How do you make antibody discovery species-specific for dogs or cats?

Species alignment can begin with canine or feline target analysis, antigen design, and platform selection. CynoCure and FeliCure options support canine and feline discovery, while caninization, felinization, Fc selection, and re-characterization can further improve compatibility for the intended pet species.

Which discovery platform should I choose for a difficult target?

The best route depends on antigen quality, membrane association, epitope goals, sample availability, and assay format. Phage display may support high-diversity or iterative screening, single-B cell workflows can preserve native pairing, and hybridoma discovery can be useful when immunization and clone expansion are practical.

Can you start with an existing antibody instead of discovering a new one?

Yes. Existing antibodies can be reviewed for sequence liabilities, species compatibility, affinity, specificity, expression, and functional performance. Engineering options may include caninization, felinization, chimeric conversion, affinity optimization, format conversion, recombinant expression, and follow-up characterization.

What assays are used to rank pet therapeutic antibody candidates?

Assay panels are target-specific and may include ELISA, flow cytometry, SPR or BLI kinetics, receptor-ligand blockade, cell binding, signaling, cytokine response, viability, reporter systems, species cross-reactivity, and negative-target counter-screens. The goal is to connect binding quality with mechanism-relevant function.

What information should I provide to start an inquiry?

Please provide the target name or sequence, intended species, disease indication, desired antibody mechanism, available antigen or assay materials, preferred discovery platform if known, and any required deliverables. Creative Biolabs can then recommend a tailored scope, milestones, and feasibility considerations.

Vet (Pet) Therapeutic Antibody Discovery Services

Pet Antibody Discovery

Species-Appropriate Antibody Leads for Companion Animal Therapeutics

Developing therapeutic antibodies for pets requires more than transferring human antibody discovery logic into a veterinary setting. Species-specific immune responses, target conservation, receptor biology, Fc compatibility, assay availability, and preclinical sample limitations can all affect whether a promising binder becomes a practical canine or feline therapeutic candidate.

Creative Biolabs supports pet therapeutic antibody research with an integrated workflow that connects target discovery, veterinary antigen generation, platform selection, lead isolation, characterization, biological functionality assays, and optional antibody engineering. Programs can begin with only a target name or sequence, or with an existing antibody that needs caninization, felinization, affinity improvement, format conversion, or deeper functional validation.

Target & Antigen

Target Strategy and Veterinary Antigen Services

Discovery success starts with target rationale and antigen quality. Creative Biolabs helps align target biology, species conservation, antigen format, and downstream screening feasibility before a full discovery campaign begins.

Pet Therapeutic Antibody Target Discovery

Target discovery and validation support integrates disease biology, sequence conservation, pathway relevance, tissue expression, accessibility, and assay readiness to prioritize actionable targets for pet antibody therapeutics.

Veterinary Antigen Services

Antigen services include peptide synthesis, recombinant protein design, expression, purification, sourcing, and quality checks to support immunization, display screening, assay development, and target engagement studies.

Discovery Routes

Species-Aware Pet Antibody Discovery Platforms

Platform selection depends on target format, available antigen, desired diversity, heavy-light pairing requirements, screening throughput, and the need for canine or feline compatibility from the beginning of discovery.

CynoCure™ Canine Antibody Discovery

CynoCure™ supports canine therapeutic antibody programs with dog-relevant discovery resources designed to identify leads better aligned with canine sequence and framework needs.

FeliCure™ Feline Antibody Discovery

FeliCure™ is tailored for feline antibody discovery, supporting projects where cat-compatible frameworks, feline target biology, and species-aware developability are central to lead selection.

Phage Display Antibody Discovery

Phage display enables high-diversity screening, epitope-focused selection, affinity maturation options, and iterative enrichment against purified proteins, peptides, domains, or selected target formats.

Single-B Cell Antibody Discovery

Single-B cell workflows can preserve native heavy-light pairing and support rapid isolation of antibodies from immunized or target-responsive repertoires when suitable samples are available.

Hybridoma Antibody Discovery

Hybridoma discovery remains valuable for robust monoclonal generation, clone expansion, screening, and antibody production when immunization-compatible antigen and screening assays are available.

Lead Evidence

Antibody Characterization and Biological Functionality Assays

Lead panels require more than binding confirmation. Creative Biolabs can evaluate sequence identity, affinity, specificity, receptor-ligand blockade, cell binding, and early biological activity to help prioritize candidates for engineering or preclinical evaluation.

Antibody Characterization

Characterization services may include clone screening, antibody sequencing, expression checks, affinity ranking, specificity testing, epitope assessment, stability observations, and reportable candidate comparison.

In Vitro Antibody Biological Functionality Assays

Functionality assays can assess target engagement, blocking activity, signaling, cytokine response, cell-based potency, immune pathway modulation, or other mechanism-linked readouts selected for the pet indication.

Candidate Optimization

Antibody Engineering for Canine and Feline Therapeutic Candidates

After lead identification, optional engineering can improve species compatibility, expression, developability, functional profile, and research-use material quality before expanded pet therapeutic antibody evaluation.

Antibody Engineering

Engineering services include caninization, felinization, chimeric formatting, Fc and isotype considerations, affinity optimization, gene synthesis, recombinant expression, purification, and re-characterization.

Discovery Workflow

Pet Therapeutic Antibody Discovery Workflow

Our workflow covers consultation of potential targets, antigen preparation, antibody discovery via selected platforms, candidate characterization, and optional engineering to develop effective pet therapeutic antibody candidates. A comprehensive target-to-engineered-candidate program is commonly planned across approximately 5 to 11 months, depending on target complexity, platform choice, assay readiness, and engineering scope.

Starting Materials Target name, gene or protein sequence, desired pet species, and therapeutic goals.

Project Design Target review, platform selection, milestone definition, and customized work plan.

Antigen Preparation Peptide synthesis, recombinant protein expression, purification, and validation.

Lead Discovery CynoCure™, FeliCure™, phage display, single-B cell, or hybridoma execution.

Characterization Binding, sequence, specificity, and initial functional confirmation of leading clones.

Engineering Optional caninization, felinization, format conversion, expression, and purified candidate delivery.

Required Starting Materials

Target name, gene sequence, or protein sequence.
Preferred therapeutic species, such as canine, feline, or multispecies.
Indication, desired mechanism, affinity, specificity, and format goals.
Available antigen, cell line, tissue, serum, or assay information.

Typical Deliverables

Project design, methods, raw data summary, and interpreted report.
Genetic sequences of identified and engineered antibody candidates.
Purified antibody samples for sponsor-side research evaluation.
Recommended next steps for characterization or preclinical study design.

Stage	Main Activities	Decision Value	Estimated Timing
Target and Antigen	Target review, construct design, peptide or recombinant antigen generation, quality assessment.	Confirms that discovery inputs fit target biology and intended species.	Typically several weeks, depending on antigen complexity.
Discovery Execution	Library screening, immunization-based discovery, B-cell isolation, hybridoma screening, or combined strategies.	Generates diverse binding leads against the pet-relevant target format.	Often 2 to 4 months after antigen readiness.
Characterization	Sequencing, binding assays, specificity checks, SPR or BLI kinetics, and functional pilot assays.	Ranks candidates by potency, selectivity, epitope behavior, and assay relevance.	Usually 1 to 2 months, depending on assay panel.
Engineering	Caninization, felinization, Fc or format selection, expression, purification, and re-testing.	Improves species compatibility and supports further pet therapeutic evaluation.	Project-specific; commonly added after lead selection.

Have a target but not a discovery route?

Share the target, species, indication, and available materials. Creative Biolabs can recommend a platform combination and milestone plan for pet therapeutic antibody research.

Open-Access Evidence

Published Data on Caninised Anti-NGF Antibody Discovery and Characterization

This study reports the generation of NV-01, a fully caninised anti-NGF monoclonal antibody developed from a rat parental antibody for canine pain research. The work follows a practical discovery-to-characterization path, including sequence adaptation, recombinant expression, purification, molecular integrity analysis, antigen binding evaluation, stability testing, Fc-related safety considerations, pharmacokinetic profiling, and assessment in a canine inflammatory pain model.

The figure supports this service-category page because it shows the type of evidence needed before a veterinary antibody candidate can move forward: SDS-PAGE purity and integrity data, accelerated storage stability, concentration-dependent NGF binding, and in vitro inhibition of NGF-driven cell proliferation. Together, these datasets illustrate how antibody discovery, species-specific engineering, analytical characterization, and functional assays can be combined into a decision-ready lead package for pet therapeutic programs.

Characterization panels for caninised anti-NGF antibody NV-01, including SDS-PAGE, stability, binding, and in vitro inhibition assay — Fig.1 Characterization of the caninised anti-NGF antibody NV-01, including purity, stability, binding, and *in vitro* functional inhibition data.^1,2

Why Choose Us

Service Advantages for Pet Therapeutic Antibody Discovery

Creative Biolabs combines veterinary biologics experience, species-aware antibody platforms, and flexible discovery modules to support companion animal therapeutic programs from early target concept to engineered antibody candidates.

Species-Matched Strategy

Canine and feline discovery paths reflect target species biology.

Integrated Workflow

Target, antigen, discovery, assays, and engineering under one program.

Platform Flexibility

Multiple routes support difficult targets and different lead profiles.

Decision-Ready Reports

Clear data packages guide candidate selection and next studies.

FAQs

Pet Therapeutic Antibody Discovery FAQs

Pet therapeutic antibodies are being investigated for oncology, inflammatory disease, chronic pain, allergy, immune-mediated disorders, and infectious disease applications. Creative Biolabs can help evaluate whether a proposed target, species, mechanism, and assay strategy are suitable for early antibody discovery.

References

Gearing, D. P., Virtue, E. R., Gearing, R. P., & Drew, A. C. "A fully caninised anti-NGF monoclonal antibody for pain relief in dogs." BMC Veterinary Research 9, 226 (2013). https://doi.org/10.1186/1746-6148-9-226
Figure reproduced from the open-access article under the Creative Commons Attribution 2.0 License, without modification.